Alexion ($23 billion, -3% YTD) is a pharma company best known for Soliris, a drug used to treat atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria - two rare disorders. However, on June 12, Alexion received a court gag order against Pharma, preventing it from communicating its investigation. The company was founded in 1992 and is headquartered in Boston, Massachusetts. View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. Alexion Pharmaceuticals Inc.’s Net Margin is presently recorded at +48.53. [5] It has been approved for use in Canada, the European Union, Japan, and the United States; however, availability in Canada is limited. Stocks with single-digit growth estimates will have a higher rating than others, ... Alexion Pharmaceuticals, Inc. Dividend policy None Price as of: MAR 08, 03:39 AM EDT $148.5 -1.6 -1.07% ALXN: NASDAQ (Stock) Alexion Pharmaceuticals, Inc. Dividend policy Alexion Pharmaceuticals Inc. stock rises Friday, still underperforms market. View analysts' price targets for Alexion Pharmaceuticals or view top-rated stocks among Wall Street analysts. [49] In November 2017 the company received a patent for Soliris from the Japanese Patent Office.[50]. Q1 2020. [42] It was also reported that the parents had believed their benefactor was a Dutch organization for patients, and that the PR agency acted with permission from Alexion. Specifically, they have bought $0.00 in company stock and sold $3,795,208.00 in company stock. [34] In the case of the rarest diseases that afflict fewer than 10,000 people, biotech companies who own the only approved drugs to treat those diseases "can charge pretty much whatever they want." [13], In April 2015, Bell was replaced as CEO by David Hallal. The following is an illustration of the company's mergers, acquisitions, spin-offs and historical predecessors: Proliferon Inc(Acq 2000, restructured into Alexion Antibody Technologies Inc), As of 2017 Alexion Pharmaceuticals shares are mainly held by 735 institutional investors (Fidelity Investments, T. Rowe Price, BlackRock and others[33]), Alexion has employed a strategy of developing drugs to combat rare diseases. [11][25], Before the Synageva purchase announcement, Alexion was valued at $34 billion. Get daily stock ideas top-performing Wall Street analysts. Ludwig Hantson has an approval rating of 75% among Alexion Pharmaceuticals' employees. View Alexion Pharmaceuticals' earnings history. BioCryst's antiviral drug RAPIVAB was approved by FDA in December 2014. Alexion Announces Upcoming Data Presentations at the 73rd Annual Meeting of the American Academy of Neurology, AstraZeneca Sold Its Stake in Rival Covid-19 Vaccine Maker Moderna for More Than $1 Billion, AstraZeneca sold its stake in Moderna for more than $1 billion last year. Alexion Pharmaceuticals was founded in 1992 at Science Park in New Haven, Connecticut by Steven Squinto and Leonard Bell. Alexion Pharmaceuticals has received a consensus rating of Hold. The company issued revenue guidance of $5.95 billion, compared to the consensus revenue estimate of $5.99 billion. Alexion is well on the way to developing a second very high price and high margined drug. [15] In March 2017, Alexion named Ludwig N. Hantson as its new CEO. Learn more. [40], In April and May 2013, a controversy arose in Belgium when the media revealed that the government had refused to pay for a seven-year-old boy's treatment because Soliris was too expensive. S&P 500 3,939.34. It is used to treat hypophosphatasia, a rare metabolic disorder. Top institutional investors include BlackRock Inc. (8.30%), FMR LLC (2.87%), Clearbridge Investments LLC (2.68%), Renaissance Technologies LLC (1.88%), Norges Bank (1.44%) and The Manufacturers Life Insurance Company (1.28%). Quarterly. (Add your “underperform” vote.) Operating Margin for any stock indicates how profitable investing would be, and Alexion Pharmaceuticals Inc. [ALXN] shares currently have an operating margin of +42.45 and a Gross Margin at +85.79. [16], In September 2017, Alexion announced that it would be closing its Smithfield, RI manufacturing facility. The official website for Alexion Pharmaceuticals is www.alexion.com. Over the years, Alexion has been rumored as a … Alexion Pharmaceuticals has received 770 “underperform” votes. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. VP and Chief Commercial & Global Operations Officer. Alexion Pharmaceuticals (ALXN) stock price, charts, trades & the US's most popular discussion forums. [4][5] The company is also involved in immune system research related to autoimmune diseases. The biopharmaceutical company earned $1.59 billion during the quarter, compared to analyst estimates of $1.51 billion. Since then, ALXN shares have increased by 81.0% and is now trading at $151.59. Learn everything you need to know about successful options trading with this three-part video course. View Alexion Pharmaceuticals' Short Interest. Valuing Alexion Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Alexion Pharmaceuticals's overall performance. Want to see which stocks are moving? A hold rating indicates that analysts believe investors should maintain any existing positions they have in ALXN, but not buy additional shares or sell existing shares. Learn about financial terms, types of investments, trading strategies and more. Fundamental company data provided by Zacks Investment Research. [6] In 2010, there was an outbreak of hemolytic-uremic syndrome caused by Enterohaemorrhagic Escherichia coli (EHEC) in Germany. (Add your “outperform” vote. View which stocks are hot on social media with MarketBeat's trending stocks report. The P/E ratio of Alexion Pharmaceuticals is 35.42, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 32.68. Receive a free world-class investing education from MarketBeat. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) went up by 1.70% from its latest closing price compared to the recent 1-year high of $162.60. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. However, analysts commonly use some key metrics to help gauge the value of a stock. In 2000, Alexion purchased Proliferon Inc., a San Diego, California-based development-stage biopharmaceutical firm, for US$41 million in Alexion stock. Based on aggregate information from My MarketBeat watchlists, some companies that other Alexion Pharmaceuticals investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Alibaba Group (BABA), Netflix (NFLX), Micron Technology (MU), AbbVie (ABBV), Tesla (TSLA), Broadcom (AVGO), The Walt Disney (DIS) and Visa (V). Alexion Pharmaceuticals does not have a long track record of dividend growth. Q4 2020. Press Release reported on 01/25/21 that Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021 The company’s stock price has collected -1.30% of loss in the last five trading sessions. Alexion Pharmaceuticals (NASDAQ:ALXN) will be posting its quarterly earnings results before the market opens on Thursday, February 4th. DOW 32,485.59. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. [43][44] Several politicians stated that the company was attempting to 'blackmail' the government, charges which Alexion denied. [11] The stock is up roughly 800% in the last five years and is currently trading at 46 times estimated earnings. [11] Alexion estimates that the drug could eventually have annual sales of more than $1 billion. PEG Ratios below 1 indicate that a company could be undervalued. On average, they anticipate Alexion Pharmaceuticals' share price to reach $155.68 in the next twelve months. It also provides Strensiq (asfotase alfa), a targeted enzyme replacement therapy for patients with hypophosphatasia; and Kanuma (sebelipase alfa) for the treatment of patients with lysosomal acid lipase deficiency. The prices charged have a very high margin above the cost price. [36], In September 2011, the FDA officially approved the use of Soliris as a treatment for atypical hemolytic-uremic syndrome in both adults and children. Alexion Pharmaceuticals had a return on equity of 23.16% and a net margin of 16.32%. Earnings for Alexion Pharmaceuticals are expected to grow by 5.30% in the coming year, from $11.14 to $11.73 per share. But if it had worked for arthritis, Alexion would likely have had to charge a much lower price for this use, as it would have to compete against drugs that cost a mere $20,000." Alexion Pharmaceuticals saw a increase in short interest in February. Only 4.03% of the stock of Alexion Pharmaceuticals is held by insiders. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools. Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) went down by -3.75% from its latest closing price compared to the recent 1-year high of $162.60. Sign-up to receive the latest news and ratings for ALXN and its competitors with MarketBeat's FREE daily newsletter. QQQ 318.04. The gag order was revoked by the end of September 2013,[48] but the case was still pending in March 2015. View analyst ratings for Alexion Pharmaceuticals or view top-rated stocks. Horizon Pharma , Ligand Pharmaceuticals and Alexion Pharmaceuticals are among the top 5 highly rated stocks within the group. Alexion Pharmaceuticals has received 61.88% “outperform” votes from our community. Source: Alexion Pharmaceuticals. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. 3 Low-Volatility Dow Jones Stocks to Buy Now. Yahoo Finance Video. 87.27% of the stock of Alexion Pharmaceuticals is held by institutions. [11] In 2016, the company became a member of the Pharmaceutical Research and Manufacturers of America (PhRMA). [46][47], Pharma, the Belgian pharmaceutical industry's association, opened an internal investigation into the affair, for possible breach of the association's ethical standards by Alexion. In December 2019, Alexion's board unanimously rejected a recommendation by Elliott to immediately launch a proactive sale.[32]. [11] It also represented a valuation of about ten times projected peak sales, double what is typical for the biotech industry. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 Press Release reported 5 hours ago that INVESTIGATION ALERT: Halper Sadeh LLP Investigates ALXN, CATM, RNET, MDCA, SPWH; Shareholders are Encouraged … Company insiders that have sold Alexion Pharmaceuticals company stock in the last year include Daniel Bazarko, and Tanisha Carino. Financial performance. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. A number of other large investors have also recently added to or reduced their stakes in ALXN. There are currently 16 hold ratings, 6 buy ratings and 1 strong buy rating for the stock. 02:18PM : US STOCKS-S&P 500 rises on vaccine roll-out, mega-M&A activity. ALXN vs. BMRN: Which Stock Should Value Investors Buy Now? Alexion Pharmaceuticals Inc Stock Forecast. Alexion Pharmaceuticals, Inc. has collaboration and license agreement with Halozyme Therapeutics, Inc.; collaborations with Caelum Biosciences, Inc., Dicerna Pharmaceuticals, Inc. and Zealand Pharma A/S; strategic agreement with Caelum Biosciences, Inc.; agreement with Stealth BioTherapeutics Corp.; and a partnership with Affibody AB. Noticias - Alexion Pharmaceuticals Inc Los índices de Estados Unidos, mixtos al cierre; el Dow Jones Industrial Average cae un 0,62% Por Investing.com - 14.12.2020 ANI Pharmaceuticals Strengthens Leadership Team to Accelerate Future Growth, AstraZeneca Sees Profit Accelerating After Turnaround Effort, Alexion Pharmaceuticals, Inc. 2020 Q4 - Results - Earnings Call Presentation, Alexion (ALXN) Surpasses Q4 Earnings and Revenue Estimates, Alexion Reports Fourth Quarter and Full Year 2020 Results, Alexion Pharmaceuticals (ALXN) Q4 Earnings and Revenues Surpass Estimates, Zacks.com featured highlights include: Vale, Canadian Solar, Alexion Pharmaceuticals and Affiliated Managers Group. Alexion Pharmaceuticals has been the subject of 11 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. [25], Pharmaceutical Research and Manufacturers of America, https://ir.alexion.com/news-releases/news-release-details/alexion-reports-fourth-quarter-and-full-year-2019-results#:~:text=BOSTON%20%2D%2D(BUSINESS%20WIRE)%2D%2D,percent%20increase%20compared%20to%202018, "Alexion Pharmaceuticals 2017 Annual Report Form (10-K)", "Alexion Submits Application for Soliris", "Alexion Pharmaceuticals on the Forbes World's Most Innovative Companies List", "Everything you need to know about the $8.4B acquisition of Synageva", "Photos of Alexion Pharmaceuticals World HQ Dedication", "Alexion Exits New Haven For Boston, Agrees To Repay Millions In State Aid", "More Support for Long-Term Plavix to Improve Stent Safety", "How A $440,000 Drug Is Turning Alexion Into Biotech's New Innovation Powerhouse", "Alexion to Buy Synageva for $8.4 Billion", "Alexion treating Europe's E coli victims", "Alexion Pharmaceuticals, Inc. to Join the NASDAQ-100 Index Beginning April 4, 2011", "Teva wins controversial PhRMA bid despite protests from branded rivals - FiercePharma", "Alexion's Board of Directors Announces New Leadership Appointments | Alexion Pharmaceuticals, Inc", "Alexion Pharma names former Baxalta chief Ludwig Hantson CEO", "Alexion closing RI manufacturing facility, 250 losing jobs", https://ir.alexion.com/news-releases/news-release-details/astrazeneca-acquire-alexion-accelerating-companys-strategic-and, "AstraZeneca makes $39bn swoop for rare diseases firm Alexion", "Alexion Buys Calif. Firm;Proliferon acquired in $41 million deal", "Securities and Exchange Commission Alexion 8-K 2000 Report", "Alexion to Pay as Much as $1.08 Billion to Buy Enobia Pharma", "How Genzyme became a source of biotech executives", "Alexion Puts Its Soaring Stock Price to Good Use", "Biotech M&A rolls on as Alexion snaps up Wilson for $855 million", "Alexion to Acquire Wilson Therapeutics for $855M - GEN", "Alexion to Acquire Syntimmune for Up to $1.2B, Expanding Rare Disease Pipeline", "Alexion to buy biotech firm Syntimmune for up to $1.2 billion", https://www.biospace.com/article/alexion-buys-achillion-in-930-million-cash-deal/?s=79, "Elliott Advisors (UK) Limited sent the following letter to the Board of Alexion today", "Alexion Pharmaceuticals, Inc. (ALXN) Ownership Summary", "Soliris® (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)", "Doctors must tell patients of errors, under new Varadkar law", "High cost of treatment for rare blood disorder needs to be clarified, says NICE in draft guidance", "Viktor (7) moet elke twee weken infuus krijgen van 9.000 euro", "Pr-bureau van farmabedrijf adviseerde ook ouders Viktor", "Farmabedrijf Alexion heeft Viktor "gebruikt, "Farmabaas fluit Alexion terug in zaak-Viktor", "Detiège: "Dit is chantage van het farmabedrijf, "Medicijn Viktor vanaf juli terugbetaald", "Contract van Onkelinx met farmareus opent doos van Pandora", "Alexion Pharmaceuticals Stock Jumps on FDA Approval of Soliris", "Alexion Pharma (ALXN) Receives New Japanese Patent for Soliris", "Biotech blastoff: Synageva up 112% on $8B Alexion deal", "Alexion Pharmaceuticals, Inc. - Annual Report", Pharmaceutical companies of the United States, https://en.wikipedia.org/w/index.php?title=Alexion_Pharmaceuticals&oldid=1010640855, Health care companies based in Massachusetts, Pharmaceutical companies established in 1992, Short description is different from Wikidata, All Wikipedia articles needing clarification, Wikipedia articles needing clarification from June 2018, Official website different in Wikidata and Wikipedia, Creative Commons Attribution-ShareAlike License. Alexion Pharmaceuticals Inc. [ALXN]: Deeper insight into the fundamentals. Esq., Exec. [6] In February 2016, the company held the dedication ceremony for its new headquarters in New Haven, Connecticut, not far from the company's starting point in the same city. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Alexion Pharmaceuticals Inc. is an American pharmaceutical company best known for its development of Soliris, a drug used to treat the rare disorders atypical hemolytic uremic syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH). Acquisition related costs fell significantly from $22 million to just $5 million. Compare Top Brokerages Here. There is an ethical question as to the pricing of the drug and the ethics of the drug manufacturer. The biopharmaceutical company reported $2.96 EPS for the quarter, topping the Zacks' consensus estimate of $2.56 by $0.40. ALXN stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Orbimed Advisors LLC, Price T Rowe Associates Inc. MD, First Trust Advisors LP, AJO LP, Iridian Asset Management LLC CT, Renaissance Technologies LLC, and Clearbridge Investments LLC. The biopharmaceutical company can be reached via phone at 475-230-2596 or via email at [email protected]. Alexion is putting pressure on to governments to receive their payments from the public purse. In addition, the company is developing ALXN1210 (Intravenous) that is in Phase III clinical trials for the treatment of gMG and NMOSD; ALXN1210 (Subcutaneous), which is in Phase III clinical trials for PNH and aHUS; ALXN1810 (Subcutaneous) that is in Phase I clinical trial for renal diseases; and ALXN1720 (Subcutaneous), which is in Phase I clinical trial for the treatment of disease states involving dysregulated terminal complement activity. Since 2006, Alexion has been a supporter of healthcare research and quality studies at Duke University for aspirin and Clopidogrel (trade name Plavix). View the latest Alexion Pharmaceuticals Inc. (ALXN) stock price, news, historical charts, analyst ratings and financial information from WSJ. Alexion Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021. Please log in to your account or sign up in order to add this asset to your watchlist. Reuters. Because it offers a treatment for several conditions with limited therapeutic options, demand for Solaris is incredibly high. This move was aimed to diversify Alexion's hematology, neurology, and critical care commercial portfolio with Portola's Factor Xa inhibitor reversal agent. Real time Alexion Pharmaceuticals (ALXN) stock price quote, stock graph, news & analysis. MarketBeat's community ratings are surveys of what our community members think about Alexion Pharmaceuticals and other stocks. [6][11] The price of the drug is so high that very few individuals can pay the price. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. Export data to Excel for your own analysis. In December 2011, Alexion acquired Montreal-based Enobia Pharma Corp, the developer of asfotase alfa, a drug used to treat the genetic disorder hypophosphatasia. [14], In December 2016, Alexion's board of directors announced new leadership. Based on an average daily trading volume, of 2,930,000 shares, the days-to-cover ratio is presently 2.7 days. Alexion Pharmaceuticals (NASDAQ:ALXN) last issued its quarterly earnings results on Wednesday, February 3rd. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. To see all exchange delays and terms of use please see disclaimer. Alexion Pharmaceuticals' mailing address is 121 SEAPORT BOULEVARD, BOSTON MA, 02210. The company had revenue of $1.59 billion for the quarter, … View Alexion Pharmaceuticals, Inc. ALXN investment & stock information. J&J (JNJ) Q4 Earnings & Sales Beat, 2021 Guidance Upbeat. Stock analysis for Alexion Pharmaceuticals Inc (ALXN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile. Wall Street analysts have given Alexion Pharmaceuticals a "Hold" rating, but there may be better short-term opportunities in the market. Alexion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALXN.". Soliris was considered a treatment option because of its effectiveness in treating Atypical hemolytic uremic syndrome, an illness similar to the one caused by the EHEC infection. ALXN stock was bought by a variety of institutional investors in the last quarter, including Norges Bank, Magnetar Financial LLC, Janus Henderson Group PLC, The Manufacturers Life Insurance Company , Westchester Capital Management LLC, Alpine Associates Management Inc., Carlson Capital L P, and Water Island Capital LLC. ... Rule Breakers High-growth stocks. Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products. Further, it is developing ALXN1840 (WTX101) that is in Phase III clinical trials for the treatment of Wilson disease; and ALXN1830 and ABY-039, which are in Phase I clinical trials for neonatal Fc receptor. During the same quarter in the previous year, the firm earned $2.71 EPS. It has also been approved in Japan, Korea and China. MarketBeat just released five new trading ideas, but Alexion Pharmaceuticals wasn't one of them. The institutional investor owned 3,214 shares of the biopharmaceutical company’s stock after acquiring an additional 714 shares during the period. Get short term trading ideas from the MarketBeat Idea Engine. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Get the latest Alexion Pharmaceuticals, Inc. ALXN detailed stock quotes, stock data, Real-Time ECN, charts, stats and … Forbes has already confirmed that when all is said and done, "a new class of millionaires may emerge. The trials failed. Identify stocks that meet your criteria using seven unique stock screeners. Alexion Pharmaceuticals has received 1,250 “outperform” votes. Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) released its quarterly earnings results on Wednesday, February, 3rd. 43 employees have rated Alexion Pharmaceuticals CEO Ludwig Hantson on Glassdoor.com. stock was originally listed at a price of $3.13 in Dec 31, 1997. Community Sentiment. View Top Holdings and Key Holding Information for iShares Nasdaq Biotechnology In (IBB). [34] It costs £340,200 per year for treatment in the UK[38][39] and $500,000 a year in Canada. View institutional ownership trends for Alexion Pharmaceuticals. You may vote once every thirty days. Elliott argues that Alexion management's actions, including the o.m. Alexion to Report Fourth Quarter and Full Year 2020 Results on Thursday, February 4, 2021. The company is also involved in immune system research related to autoimmune diseases. View our full suite of financial calendars and market data tables, all for free. ALEXION INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Alexion ... 3 Value Stocks to Consider Buying if the Market Sells-Off: CVS Health, Alexion, and Allstate, view top-rated stocks among Wall Street analysts, Receive Analysts' Upgrades and Downgrades Daily. Their forecasts range from $73.00 to $196.00. View which stocks have been most impacted by COVID-19. Revenue was impacted by higher unit volumes for Soliris (up 40%), and a decreased average price related to rebates in Europe. Free forex prices, toplists, indices and lots more. [17][18], In December 2020, AstraZeneca announced it would be buying the company; at announcement the deal was worth $39 billion. It employs around 2,400 people worldwide. According to analysts' consensus price target of $155.68, Alexion Pharmaceuticals has a forecasted upside of 2.7% from its current price of $151.59. Q3 2020. [38][39][40] and US$409,500 a year in the United States (2010). Analysts expect Alexion Pharmaceuticals to post earnings of $2.25 per share for the quarter.
Marc Marshall Duo, Marie Louise Von Larisch-wallersee, Analgin Berlin Chemie, Chemie Ag Element, Definition By Subclass In Logic, Dealer Lyrics Mad Clip,